Please assess the completion status of the following clinical trial:

Trial Title: Study of MiniMed™ 640G Insulin Pump With SmartGuard™ in Prevention of Low Glucose Events in Adults With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 24-75 years old at time of screening.~* Diagnosed with Type 1 diabetes ≥10 years prior to screening.~* On pump therapy for ≥ 6 months prior to screening.~* Not on Real Time continuous glucose monitoring for ≥ 3 months prior to screening.~* HbA1c value ≥5.8% and ≤10.0% as assessed by local lab ≤ 15 days prior to screening or performed at screening.~* A documented Severe Hypoglycemia event ≤ 12 months prior to screening, OR Clarke score ≥4 assessed at time of screening, OR~* Gold score ≥4 assessed at time of screening.~* Subject is willing to sign and date informed consent, comply with all study procedures and wear all study devices as required during the study.~Exclusion Criteria:~* Untreated Addison's disease, thyroid disorder, growth hormone deficiency, hypopituitarism or definite gastroparesis, per investigator judgment.~* Subject is using Pramlintide (Symlin) SGLT2 inhibitor, GLP agonist at time of screening.~* Renal failure defined by creatinine clearance \<30 ml/min, as assessed by local lab test ≤ 3 months before screening or performed at screening at local lab.~* Hearing or vision impairment hindering perception of glucose display and alarms, or otherwise incapable of using the study devices, per investigator judgment.~* Current pregnancy or intention to conceive.~* Any unresolved adverse skin condition in the area of sensor placement (e.g. psoriasis, rash, Staphylococcus infection).~* Alcohol or drug abuse, other than nicotine, per investigator judgment.~* Any other disease or condition that may preclude the patient from participating in the study, per investigator judgment.~* Legally incompetent, illiterate or vulnerable person.~Randomization Criteria:~* If subjects meet the above criteria, as well as all of the following criteria assessed at the end of the run-in period, they may continue to participate in the treatment period of the study:~  * Subject has worn two weeks the sensor with transmitter during the run-in period.~ * Subject has shown acceptable tolerance of sensor wear, per investigator judgment.~ * Subject performed ≥ 4 finger stick blood glucose measurements daily, as determined by CareLink™ Clinical data upload as the mean number of SMBG/day over the past 14 days (SMBG number / day ≥ 3.5 rounds up to 4).~ * Subject showed ability to comprehend the pump training and study procedures, per investigator judgment.

- Gender: ALL
- Minimum Age: 24 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): MiniMed™640G and Suspend before Low feature of SmartGuard™ turned on.
- Control (Type: ACTIVE_COMPARATOR): MiniMed™640G alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete